DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD

Information source: Noven Therapeutics
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Attention Deficit Hyperactivity Disorder

Intervention: Methylphenidate Transdermal System (Drug); Placebo (Drug); Concerta (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Noven Therapeutics

Summary

Study designed to evaluate the safety and efficacy of MTS compared to placebo with reference to CONCERTA« in pediatric subjects diagnosed with ADHD.

Clinical Details

Official title: A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) vs. CONCERTA« in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The primary objective of this study is to evaluate, under controlled conditions, the safety and efficacy of SPD485 (MTS) compared to placebo with reference to CONCERTA®, as determined by the change in the clinician completed ADHD-RS-IV at each visit.

Secondary outcome:

CTRS-R, CPRS-R, CGI, PGA scores

Treatment emergent AEs, dermal evaluations, PK

Detailed description: This is a phase III, randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose optimization study designed to evaluate the safety and efficacy of MTS (12. 5, 18. 75, 25, and 37. 5 cm2) compared to placebo with reference to CONCERTA« in pediatric subjects diagnosed with attention deficit hyperactivity disorder (ADHD).

Eligibility

Minimum age: 6 Years. Maximum age: 12 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- male or female aged 6-12 years

- females of Child-bearing Potential (FOCP) must have a negative serum beta Human

Chorionic Gonadotropin (HCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline.

- a primary diagnosis of ADHD based on a detailed psychiatric evaluation

- a total score of =>26 on the ADHD-RS-IV at the Baseline Visit

- a minimum level of intellectual functioning, as determined by an IQ (based on KBIT)

score of 80 or above

- no comorbid illness that could affect safety or tolerability or in any way interfere

with the subject's participation in the study. EXCLUSION CRITERIA:

- a current, controlled (requiring a restricted medication) or uncontrolled, comorbid

psychiatric diagnosis (except ODD) with significant symptoms such as Post Traumatic Stress Disorder (PTSD), psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder

- a known non-responder to psychostimulant treatment

- overweight (Body Mass Index (BMI)-for-age >90th percentile)

- a history of seizures during the last 2 years (exclusive of infantile febrile

seizures), a tic disorder, a current diagnosis and/or family history of Tourette's Disorder.

- Conduct Disorder.

- Subject has taken an investigational drug within 30 days prior to Screening.

Locations and Contacts

Additional Information

(FDA Recall Information)

(FDA-approved label)

Starting date: September 2004
Last updated: June 23, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017